Saturday, February 21, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Politics & Law

Black Swans of Health Policy

The black swans are in black robes.

Daily Remedy by Daily Remedy
January 3, 2024
in Politics & Law
0
Black Swans of Health Policy

Wesley Tingey

Election years affect health policy in funny ways. There’s always one Black Swan event. This year will be no different. In recent years, we’ve been conditioned to worry about some new law or executive mandate.

This time though, don’t worry about the healthcare laws. Worry about the changing legal interpretations of existing healthcare laws. And don’t watch the politicians. Watch the judges. The courts, both state and federal, are set to play an outsized role in health policy in the coming months. That’s not a good thing.

Since the interpretation of health laws determine its implementation, by reinterpreting existing health laws, the courts effectively enact new health care laws through judicial fiat. Unlike legislative actions on health policy that prove to be unpopular, there’s no voter retribution to be had. Judges are appointed, not elected. And in the case of federal judges, that appointment’s for life.

On the docket are two cases that will have major implications for years to come: Braidwood v. Becerra and Alliance for Hippocratic Medicine v. FDA.

Both cases might appear to be unique. Braidwood v. Becerra challenges the federal government’s ability to negotiate drug prices. Alliance for Hippocratic Medicine v. FDA challenges abortion medication access via telemedicine. But the broader theme is what matters most. How much leeway should we give administrative agencies when they implement healthcare laws?

There’s no easy answer and each side has objectively strong arguments. But the arguments themselves are less important than how they get resolved. In both cases, the final arbitrators won’t be clinically trained physicians or health administrators. It’ll be judges. We never question the validity of this because we just accept it as constitutional gospel.

It’s time we start questioning the ability of judges to properly adjudicate complex health issues. Other similarly complex issues, like immigration and bankruptcy, have their own court system. Judges appointed to those courts have special training and are subject matter experts in those fields of law.

Healthcare has no such court system. There’s an academic program, almost akin to a post-doctorate for lawyers and legal scholars, known as a Master of Laws (LLM) in health law. It provides additional legal training for complex health legal matters. But judges overseeing healthcare cases aren’t required to have it. Nor are judges with an LLM in health law specially assigned to healthcare litigation.

This is concerning when we think about the impact of a single ruling by a judge. With the stroke of a pen, through a stay order, a judge can ban certain forms of access to medical care or restrict insurance coverage for swaths of patient populations. Do we really want someone who has little to no health policy education or specialized health law training to wield such power?

We’ll always have tension between healthcare and law. Health policy is designed to be this way, for better or for worse. When healthcare boils into health policy, there’ll always be litigants involved. And with that, there’ll always be judges. I just hope those judges have specialized training in health law so they make clinically informed rulings.

After all, we require physicians to go through extensive training before they practice medicine. We should require the same for judges adjudicating complex health litigation. We’ve seen what happens when judges make rulings on health policy with little consideration for clinical data or patient care. If a physician behaved in such a way, there’d be swift repercussions.

The legal system isn’t designed to have the same degree of checks and balances for judges. This makes the need for additional, specialized health law training all the more important. Until we require our judges to be knowledgeable on the nuances of health law, we’ll continue to see rulings that are based on equal parts personal moralizations and clinical fundamentals.

It’s this very concoction that produce this year’s Black Swan event.

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The Prevention Gap in Dementia Care

    The Prevention Gap in Dementia Care

    0 shares
    Share 0 Tweet 0
  • Healthcare in Space

    1 shares
    Share 0 Tweet 0
  • Healthcare Natural Rights

    0 shares
    Share 0 Tweet 0
  • Heat Safety Tips Every Pregnant Mother Should Know

    0 shares
    Share 0 Tweet 0
  • What is the 411 on the New 988 Hotline?

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy